Every investor pitch is a clarity test. You cannot hide behind complexity when you have three minutes and someone who does not yet care. Here is what the experience of pitching Qlupod AG intensively has revealed about the product, the customer, and the assumptions we had never properly tested.
The most useful thing about pitching your product to people who genuinely do not care about it is that you find out, quite rapidly, what it actually is. Not what the internal documentation says it is. Not what the pitch deck summary claims. What it actually is – distilled to the three sentences that either make a thoughtful stranger lean forward, or reach for their phone. Finding those three sentences for Qlupod AG took considerably longer than it should have, and the process of finding them taught us things about our own product that two years of building had not.
These are the lessons worth sharing – not as a post-mortem on mistakes, but as a map of the territory that any health technology founder will eventually need to navigate.
Lesson One: The Problem Has to Land Before the Product
Like most technically-oriented founding teams, Qlupod AG’s first instinct in early pitches was to lead with the device. Five vital signs. One handheld unit. Medical-grade accuracy. Certified under European MDR. App integration. Optional clinical data sharing through QluDoc. All of this is accurate. None of it was landing the way it needed to.
What changed the dynamic – in investor meetings, in accelerator challenges, in conversations with potential clinical partners – was learning to lead with the problem rather than the solution. The problem is: a person managing hypertension sees their GP perhaps four times a year. Between those visits – 350 days of their cardiovascular life – nobody is watching. Blood pressure trends that develop gradually over six weeks, reaching clinically significant levels, are completely invisible to the clinical system until the next appointment. Atrial fibrillation episodes that occur at midnight and resolve by morning leave no trace in any clinic record. Morning hypertension – the form of elevated blood pressure most predictive of cardiovascular events – routinely goes undetected because most clinic appointments fall in the afternoon.
When the pitch leads with these problems, the product becomes obvious rather than requiring explanation. When it leads with the product’s features, the problems remain abstract and the features feel like answers to questions nobody has asked.
Lesson Two: Your Customer Is More Than One Person
Qlupod AG began with a clear mental model of its primary customer: the patient with a chronic cardiovascular condition, monitoring their vital signs at home between clinic visits. That mental model is accurate – but incomplete in ways that became clear under the pressure of investor questioning.
A more complete picture of Qlupod AG’s customer includes the GP who needs better data to make better decisions about a patient they see for ten minutes four times a year. The cardiologist who wants a six-week blood pressure trend rather than a patient’s imperfect recall of recent readings. The adult child who is worried about an elderly parent living alone and who wants objective information rather than the reassurance of a phone call. The family caregiver who needs to know when a reading warrants a clinical call and when it represents normal variation. The health system that is trying to reduce hospital readmissions for heart failure patients by monitoring fluid status at home.
Each of these customers has a different problem, a different decision they need support making, and a different version of QluPod’s value proposition that resonates with them. Getting genuinely clear on this – not as a slide listing user personas, but as a real understanding of how different users experience the product’s value – has shaped both the product roadmap and the communication strategy in ways that only became possible under the pressure of investor questions that did not accept vague answers.
Lesson Three: Conviction Is Read as a Signal
The most consistent observation from investor conversations that progressed to follow-up discussions – versus those that did not – was not about the product’s feature set, the market size, or the competitive landscape. It was about whether the founders communicated genuine, grounded conviction about why Qlupod AG would succeed in this specific market, at this specific moment, against this specific set of alternatives.
There is a meaningful difference between enthusiasm and conviction. Enthusiasm is easy to generate and easy to read as performed. Conviction – the kind that comes from having genuinely worked through the hard questions, identified the real obstacles, and developed a specific and honest account of why the path forward is viable – is slower to build and more immediately credible when present. Sophisticated investors read this difference quickly. They are not looking for founders who think everything will go well. They are looking for founders who have thought deeply about why it could go badly, have a realistic response to each risk, and are going anyway because the opportunity is worth it.
Building that kind of conviction is not a communication exercise. It is a thinking exercise – a genuine interrogation of assumptions, a real engagement with the competitive and regulatory landscape, and an honest assessment of the team’s capabilities relative to the task. The pitch is the output. The thinking is the work.
“Investors do not fund products. They fund founders who know something the market has not yet priced in – and who can explain, specifically, what that is.”
Lesson Four: The Questions You Cannot Answer Are the Most Valuable
In every round of intense pitching, there are questions that expose genuine gaps in thinking – assumptions that have been made implicitly, areas where the analysis stopped short of the level of specificity that real clinical or commercial progress requires. These questions are uncomfortable in the moment and invaluable afterward.
For Qlupod AG, some of those questions were about reimbursement pathways in specific European markets – the detailed, country-by-country analysis of how home monitoring devices are paid for, and by whom, that is more complex than a general statement about the European digital health market can capture. Others were about the clinical evidence supporting specific use cases: what does the clinical literature actually say about the effectiveness of home blood pressure monitoring in reducing cardiovascular events in patients with specific risk profiles? The answers to these questions exist. Having them
fluent and specific requires doing the work.
The founder who welcomes these questions, genuinely engages with them, and follows up with the detailed answer, is demonstrating something more valuable than the ability to give a polished pitch. They are demonstrating the intellectual honesty and the work ethic that are the most reliable predictors of the ability to navigate the genuinely hard problems that building a health technology company will inevitably produce.
What We Know Now That We Did Not Before
Qlupod AG is a better-defined company for having pitched intensively – through investor meetings, through the challenges of The Founder Games, through clinical partnership conversations that ask the same fundamental questions in different registers. The pitch process has forced clarity that internal discussion had not produced. It has identified assumptions we had made without testing, objections we had not considered, and use cases we had systematically underweighted in our own thinking.
The product itself has not changed. Our understanding of who it serves, how it creates value, and why it will succeed in the competitive and regulatory landscape it operates in, is substantially sharper than it was before we started being asked these questions by people who had no reason to accept incomplete answers. That sharpness is worth the discomfort. We are grateful for every investor who pushed back, and every mentor who challenged a claim we had taken for granted.
Conclusion
Pitching is not a performance to be optimised after the product is built. It is a thinking tool to be used throughout the building process – a discipline that forces the clarity of articulation that genuine product and market understanding requires. Health technology, with its regulatory complexity, its clinical validation requirements, and its multi-stakeholder customer landscape, needs this clarity more than most sectors. The founders who find it early build faster. The ones who find it only under investor pressure build more slowly than they needed to. Starting the rigorous self-interrogation sooner is always the better path.
English 
German 
French 
Italian 
Spanish 
Albanian 
Serbian 
Macedonian 
Greek